Clinical characteristics and outcomes of first diagnosed atrial fibrillation: Insights from 2 prospective registries in Europe and Asia.

Background: Clinical characteristics and outcomes in patients with atrial fibrillation (AF) vary from diagnosis to advanced stages.

Objective: To assess differences in characteristics and outcomes between patients with first diagnosed AF and known AF.

Methods: A post hoc analysis of 2 prospective registries from Europe and Asia.

Ethnic differences in clinical outcomes following major bleeding in atrial fibrillation patients: a report from two prospective regional registries in Europe and Asia.

Aims: To investigate differences in clinical presentation and prognosis between East Asians and Europeans with atrial fibrillation (AF) who have experienced major bleeding (MB).

Methods And Results: We analysed two prospective registries enrolling AF patients from the Asian-Pacific Heart Rhythm Society (APHRS) and EURObservational Research Programme (EORP). Ethnicity was inferred by enrolment country.

Clinical phenotype of anticoagulant discontinuation and the long-term prognosis in atrial fibrillation patients with high bleeding risk: A report from the GLORIA-AF registry.

Background: Discontinuation of oral anticoagulants (OACs) in patients with atrial fibrillation (AF) at high risk of bleeding is commonly seen.

Objective: This study aimed to explore risk factors leading to OAC discontinuation and the impact on clinical events in patients with AF at high bleeding risk.

Methods: From the prospective, multicenter Global Registry on Long-Term Antithrombotic Treatment in Patients With Atrial Fibrillation study, we analyzed, by OAC discontinuation, all-cause death, cardiovascular (CV) death, major adverse CV events (MACEs), thromboembolism (TE), major bleeding, stroke, and myocardial infarction during follow-up.

Clinical associations and prognosis in Asian and European patients with symptom-controlled atrial fibrillation: Insights from two prospective registries in Europe and Asia.

Background: Clinical associations and prognosis of patients with symptom-controlled AF (scAF) remain poorly understood.

Methods: We analysed data from the Asian-Pacific Heart Rhythm Society and EURObservational Research Programme registries. Based on the European Heart Rhythm Association (EHRA) score, patients were classified as scAF (EHRA I or II) or symptomatic AF (EHRA III or IV).

Long-term clinical outcomes of oral anticoagulation in the older patients with atrial fibrillation aged ≥80 years: a report from the GLORIA-AF registry phase III.

Background: Older age increases the risk of thromboembolism (TE) and major bleeding in atrial fibrillation (AF) patients, but limited evidence exists regarding the older population (age ≥ 80) especially from different global regions. Data on benefits of oral anticoagulants in these very old individuals are also limited.

Methods: From the prospective, multicenter Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation registry, we analysed by age all-cause death, cardiovascular death, major adverse cardiovascular events (MACE), TE, major bleeding, stroke, and myocardial infarction (MI) over 3-years follow-up.

Stroke risk stratifications according to CHA2DS2-VASc vs. CHA2DS2-VA in patients with atrial fibrillation: insights from the GLORIA-AF registry.

Aims: Whether the adoption of CHA2DS2-VA score, the sex-independent version of the CHA2DS2-VASc score is beneficial for stratifying risk of stroke in patients with atrial fibrillation (AF) remains controversial.

Methods And Results: Utilizing the data from the global, multicentre and prospective GLORIA-AF Registry Phase III, we compared the performances of CHA2DS2-VA and CHA2DS2-VASc scores in stratifying the risk of ischaemic stroke and thromboembolism (TE), and compared the risk of ischaemic stroke and TE, and the use of oral anticoagulants in male and female patients with AF. A total of 21 260 AF patients with available data were included in the analysis (mean age 70.

Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III.

Renal function, assessed by creatinine clearance (CrCl), affects the efficacy and safety of oral anticoagulant (OAC) therapy in patients with atrial fibrillation (AF). To investigate the association between CrCl and the risk of clinical adverse events and compare the safety profiles of vitamin K antagonists (VKA) and non-vitamin K antagonist oral anticoagulants (NOAC). Patients with newly diagnosed AF (< 3 months before baseline visit) were collected from the prospective Global Registry on Long-Term Oral Anti-Thrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry Phase III.

Number of Previous Strokes and the Association With Clinical Outcomes of Patients With Atrial Fibrillation: Longitudinal Data From the GLORIA-AF Registry.

Background: Patients with atrial fibrillation (AF) who suffered a previous stroke are at increased risk of recurrent thromboembolic events and other major outcomes. The impact of the number of stroke episodes on the natural history of patients with AF is still unclear.

Methods And Results: Using data from the international, multicenter, and prospective GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation) Registry Phase III, we categorized patients with a recent diagnosis of non-valvular AF according to the number of previous strokes (either 0, 1, or ≥2 episodes).

In HFpEF, semaglutide reduced a composite of worsening HF or CV death.

GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

Early-stage hypertension defined by the 2017 ACC/AHA blood pressure guideline carries excessive cardiovascular risk in axial spondyloarthritis patients.

Background: Hypertension (HTN) is the most important modifiable risk factor for the development of cardiovascular events (CVEs). Patients with axSpA are also associated with an increased risk of future CVE.

Objectives: To ascertain whether baseline early-stage HTN is a predictor of future CVE in addition to inflammation in patients with axial spondyloarthritis (axSpA).

Cardiovascular benefits and safety profile of macrolide maintenance therapy in patients with bronchiectasis.

Background: Macrolide maintenance therapy (MMT) has demonstrated notable efficacy in reducing exacerbation in patients with bronchiectasis, which is a major risk factor for cardiovascular events. However, a comprehensive assessment of the cardiovascular benefits and safety profile of MMT in this population is lacking.

Methods: This territory-wide cohort study analysed patients diagnosed with bronchiectasis in Hong Kong between 2001 and 2018.

Long-term risks and benefits of oral anticoagulation in atrial fibrillation patients with cancer: A report from the GLORIA-AF registry.

Background: Anticoagulation therapy in patients with atrial fibrillation (AF) and concomitant cancer can be challenging due to the significantly increased risk of both embolism and bleeding. Moreover, the benefits and risks of vitamin K antagonists (VKA, eg. warfarin) versus non-vitamin K antagonist oral anticoagulants (NOACs) in such patients are less well understood.

Impact of inflammation and anti-inflammatory therapies on the incidence of major cardiovascular events in patients with ankylosing spondylitis: A population-based study.

Objective: To examine the independent effect of inflammatory burden and various treatments on the risk of incident major adverse cardiovascular events (MACE) in ankylosing spondylitis (AS) patients.

Methods: AS patients were retrospectively selected from a territory-wide database between 2006 and 2015, and were followed until the end of 2018. The primary outcome was the first occurrence of MACE.

Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study.

Objectives: Cardiovascular event (CVE) risk in rheumatoid arthritis (RA) was increased by glucocorticoids (GC) use. Whether there is a threshold dose and duration of GC use beyond which will increase CVE rate remains controversial. We studied the time-varying effect of GC and its dose on the risk of incident major adverse cardiovascular events (MACE) in patients with RA.

DAPSA, carotid plaque and cardiovascular events in psoriatic arthritis: a longitudinal study.

Objective: To examine whether Disease Activity in Psoriatic Arthritis (DAPSA) reflecting the inflammatory component of psoriatic arthritis (PsA) can predict cardiovascular (CV) events independent of traditional CV risk factors and subclinical carotid atherosclerosis.

Methods: A cohort analysis was performed in patients with PsA who had been followed since 2006. The outcome of interest was first CV event.